Quest Magazine

Sarepta Announces Revised Timeline for Eteplirsen FDA Application

Boys with Duchenne muscular dystrophy between the ages of seven and 16 are now being recruited to participate in a phase 3 clinical trial to evaluate the effectiveness and safety of eteplirsen in treating DMD.

SMA: Further Data on ISIS-SMNRx Shows Promising Results

Isis Pharmaceuticals, developer of the experimental spinal muscular atrophy (SMA) drug ISIS-SMNRx, revealed positive results from phase 2 clinical studies of the drug focusing on infants and children with SMA. The new data, which was shared on October 10 by ISIS representatives attending the 19th International World Muscle Society Congress in Berlin, included the following highlights:

LEMS: Firdapse Study Shows Encouraging Results

MDA Team Momentum Fights Back Against Muscle Disease at The 2014 Bank of...

MDA Names Dr. Grace Pavlath to Head Scientific Program as Research Department Intensifies Focus on Ushering Treatments Through Drug Pipeline

National Association of Letter Carriers Raises $1.4 Million to Help Fight Muscle Disease

CITGO Raises $13.6 Million to Help Fight Muscle Disease

IAFF Raises $28 Million To Fight Muscle Disease

Sponsors, Celebrities and Donors Give Generously Through MDA Show of Strength Telethon

$52.3 Million and Counting on the MDA Show of Strength Telethon